Active-ingredient Dossier
Apixaban
Active-ingredient Dossier for Apixaban (anticoagulant). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.
- Brand: ELIQUIS
- Brand: APEXA
- Brand: APIXABAN PHARMACOR
- Brand: APIXABAN-APX
- Brand: APIXOR
- Brand: ALEXIBIC
- Therapeutic area: Cardiology
- Therapeutic area: Neurology
What is
Apixaban Apixaban is an anticoagulant active ingredient.
Australian brands containing
Apixaban The following brands containing apixaban are registered on the ARTG: — ELIQUIS — APEXA — APIXABAN PHARMACOR — APIXABAN-APX — APIXOR — ALEXIBIC — ALIPIX — APIBAX — APIBIC — APIXABAN
Therapeutic areas
Apixaban is registered across three therapeutic areas: Neurology (23 brands), Cardiology (3 brands), and Haematology (3 brands).
Sponsor landscape
Apixaban is marketed by 12 sponsors, including Alembic Pharmaceuticals, Arrotex Pharmaceuticals, Pharmacor, Nova Pharmaceuticals, Cipla, and Bristol-Myers Squibb.
PBS and regulatory activity
One brand containing apixaban has PBS-listed items, with the latest PBS schedule date of 1 May 2026. In the 2024–25 financial year, the government cost for apixaban products was approximately $274.9 million across 4.24 million scripts. The latest PBAC outcome for apixaban was recorded on 1 November 2017, and the latest AusPAR was published on 15 May 2015.